What was Regeneron's revenue in Q1 2026?

Regeneron's revenue was $3.8 billion in Q1 2026, up 8.6% year-over-year.

What were Regeneron's key products in Q1?

Key products were Dupixent ($3.0 billion sales) and Eylea HD ($1.5 billion sales).

Did Regeneron provide future guidance?

Regeneron did not provide specific quarterly guidance but outlined plans to expand Dupixent.

Regeneron Q1 2026 Earnings Beat Estimates on Dupixent, Eylea HD Strength

Q: Why did Regeneron's stock fall despite beating estimates?

The stock fell due to a 10% decline in total Eylea sales and intensifying competition in the ophthalmology market.

Regeneron Pharmaceuticals (REGN) beat Q1 2026 earnings estimates, with revenue of $3.8B and EPS of $11.45, fueled by Dupixent and Eylea HD growth. The stock fell 2% post-market due to declining total Eylea sales and rising competition.

Regeneron Pharmaceuticals (REGN) reported first-quarter 2026 results that surpassed analyst expectations, with revenue of $3.8 billion and earnings per share of $11.45. Despite the strong performance, shares slipped 2% in after-hours trading.

Key Financial Results

Metric	Q1 2026	Q1 2025	Change
Revenue	$3.8B	$3.5B	+8.6%
Net Income	$1.2B	$1.1B	+9.1%
EPS	$11.45	$10.20	+12.3%

Highlights from the Report

Dupixent: Record sales of $3.0 billion, up 15% year-over-year, driven by increased demand in asthma and atopic dermatitis indications.
Eylea HD: Sales reached $1.5 billion, but total Eylea franchise (including standard dose) fell 10% to $2.0 billion due to competition from biosimilars.

Guidance

Regeneron did not provide specific quarterly guidance but reiterated plans to expand Dupixent into new indications and advance its pipeline.

Impact on Stock

Despite the earnings beat, REGN stock declined about 2% in after-hours trading as investors focused on the decline in total Eylea sales and intensifying competition in the ophthalmology market.

What This Means for Investors

The results highlight Dupixent's strength as a key growth driver for Regeneron, but the Eylea decline underscores competitive challenges. Investors should monitor competition in the eye care segment and the success of new pipeline candidates.